Fanconi's Syndrome Associated with Prolonged Adefovir Dipivoxil Therapy in a Hepatitis B Virus Patient.
- Author:
Young Kul JUNG
1
;
Jong Eun YEON
;
Jong Hwan CHOI
;
Chung Ho KIM
;
Eun Suk JUNG
;
Ji Hoon KIM
;
Jong Jae PARK
;
Jae Seon KIM
;
Young Tae BAK
;
Kwan Soo BYUN
Author Information
1. Department of Internal Medicine, Gachon University of Medicine and Science Gil Medical Center, Incheon, Korea.
- Publication Type:Case Report
- Keywords:
Fanconi syndrome;
Adefovir;
Chronic hepatitis B
- MeSH:
Adenine;
Fanconi Syndrome;
Hepatitis;
Hepatitis B;
Hepatitis B virus;
Hepatitis B, Chronic;
HIV;
Humans;
Middle Aged;
Organophosphonates;
Osteomalacia
- From:Gut and Liver
2010;4(3):389-393
- CountryRepublic of Korea
- Language:English
-
Abstract:
Adefovir dipivoxil (ADV) is commonly used as an antiviral agent in the treatment of chronic hepatitis B or human immunodeficiency virus infection. Nephrotoxicity has been shown to occur at daily dosages of 60-120 mg. Fanconi's syndrome is a generalized dysfunction of the renal proximal tubular cells, which is usually accompanied by complications. Here we report a case of Fanconi's syndrome in a chronic hepatitis B patient who had been treated with a prolonged regimen of ADV at 10 mg/day. A 47-year-old man complained of severe back and chest-wall pain. He had chronic hepatitis B and had been treated with ADV at a daily dose of 10 mg for 38 months. He was hospitalized because of severe bone pain, and laboratory and radiologic findings suggested a diagnosis of Fanconi's syndrome with osteomalacia. After discontinuation of the ADV, he recovered and was discharged from hospital. His laboratory findings had normalized within 2 weeks. This case indicates that Fanconi's syndrome can be acquired by a chronic hepatitis B patient taking ADV at a conventional dosage of 10 mg/day. Therefore, patients treated with long-term ADV should be checked regularly for the occurrence of ADV-induced Fanconi's syndrome.
